Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

0368977 - ÚPT 2012 RIV US eng J - Journal Article
Keunen, O. - Johansson, M. - Oudin, A. - Sanzey, M. - Rahim, S. A. - Fack, F. - Thorsen, F. - Taxt, T. - Bartoš, M. - Jiřík, Radovan - Miletic, H. - Wang, J. - Stieber, D. - Stuhr, L. - Moen, I. - Rygh, C. B. - Bjerkvig, R. - Niclou, S.
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
Proceedings of the National Academy of Sciences of the United States of America. Roč. 108, č. 9 (2011), s. 3749-3754. ISSN 0027-8424. E-ISSN 1091-6490
Institutional research plan: CEZ:AV0Z20650511
Keywords : angiogenesis * glioma * metabolism * perfusion
Subject RIV: FS - Medical Facilities ; Equipment
Impact factor: 9.681, year: 2011

Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on tumor burden, recurrence, and vascular physiology are unclear. We therefore determined the tumor response to bevacizumab at the phenotypic, physiological, and molecular level in a clinically relevant intracranial GBM xenograft model derived from patient tumor spheroids. Using anatomical and physiological magnetic resonance imaging (MRI), we show that bevacizumab causes a strong decrease in contrast enhancement while having only a marginal effect on tumor growth. Interestingly, dynamic contrast-enhanced MRI revealed a significant reduction of the vascular supply, as evidenced by a decrease in intratumoral blood flow and volume and, at the morphological level, by a strong reduction of large- and medium-sized blood vessels. Electron microscopy revealed fewer mitochondria in the treated tumor cells.
Permanent Link: http://hdl.handle.net/11104/0203162